Aigen Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-83,314
Closed -$2.07M 726
2025
Q4
$2.07M Buy
+83,314
New +$2.1M 0.48% 47
2025
Q1
Sell
-73,486
Closed -$1.95M 964
2024
Q4
$1.95M Buy
73,486
+35,937
+96% +$975K 0.34% 66
2024
Q3
$1.09M Buy
+37,549
New +$1.1M 0.21% 134
2024
Q2
Sell
-94,301
Closed -$2.62M 965
2024
Q1
$2.62M Buy
94,301
+64,192
+213% +$1.78M 0.57% 24
2023
Q4
$867K Buy
+30,109
New +$910K 0.15% 184
2023
Q2
Sell
-357,896
Closed -$14.6M 918
2023
Q1
$14.6M Buy
+357,896
New +$15.5M 2.01% 2
2022
Q3
Sell
-47,789
Closed -$2.51M 716
2022
Q2
$2.51M Buy
+47,789
New +$2.44M 0.42% 65
2022
Q1
Sell
-104,900
Closed -$6.03M 946
2021
Q4
$6.03M Buy
+104,900
New +$5.2M 0.37% 53
2021
Q3
Sell
-217,104
Closed -$8.5M 613
2021
Q2
$8.5M Buy
+217,104
New +$8.44M 1.48% 9
2020
Q4
Sell
-88,997
Closed -$3.1M 981
2020
Q3
$3.1M Sell
88,997
-17,614
-17% -$618K 0.4% 49
2020
Q2
$3.31M Buy
106,611
+94,194
+759% +$3.2M 0.42% 31
2020
Q1
$385K Buy
+12,417
New +$423K 0.05% 519

Other funds holding PFE

Aigen Investment Management's PFE Position: Q1 2026 in Review

Aigen Investment Management sold out of Pfizer (PFE) in Q1 2026, closing a stake of 83,314 shares — an estimated $2.07M sold.

Aigen Investment Management first reported a position in PFE in Q1 2020 and held it in 12 quarters. The position peaked at $14.6M in Q1 2023. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Aigen Investment Management reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 83,314 Pfizer shares in Q1 2026, an estimated $2.07M.
  • Aigen Investment Management first reported a position in Pfizer in Q1 2020 and held it in 12 quarters.
  • Aigen Investment Management's Pfizer position peaked at $14.6M in Q1 2023.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.